Novo Nordisk faced a setback with its cardiovascular treatment, ziltivekimab, as the ZEUS trial failed to show significant benefits in reducing major cardiovascular events despite confirming its effectiveness in reducing inflammation markers. The trial involved over 6,300 participants but resulted in no difference in rates of cardiovascular death or heart attacks between those receiving the drug and a placebo. Although serious infections were more common in the treatment group, overall adverse event rates were similar. Novo’s attempts to expand beyond its diabetes and obesity portfolio now hinge on two upcoming trials, HERMES and ARTEMIS, expected to report results in 2027. However, analysts remain skeptical about the potential for positive outcomes.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://european-biotechnology.com/latest-news/zeus-failure-clouds-future-of-novos-cardiovascular-plans/
